{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:06:27Z","timestamp":1786125987186,"version":"build-2736575974"},"reference-count":29,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Olanzapine doses in adults with treatment-resistant schizophrenia or treatment-resistant schizoaffective disorder have been compared in a few open-label trials, with higher doses associated with increased symptom improvement. The most significant adverse effects observed at off-label doses above 30 mg\/day have been weight gain, sedation, or drowsiness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study aimed to evaluate patient factors and outcomes in adult patients admitted to a county psychiatric hospital that received high-dose olanzapine therapy (HD-olanzapine, \u226540 mg\/day) compared with standard-dose olanzapine (SD-olanzapine, 5-30 mg\/day). Patients 18 years or older were included if they received at least 5 days of scheduled olanzapine treatment for psychotic symptoms or psychosis while admitted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Subjects on HD-olanzapine (n = 139) and SD-olanzapine regimens (n = 70) were on average 35 years of age, and most were White. There was no statistical difference regarding 30-day all-cause readmissions, 30-day all-cause emergency-treatment service visits, or average duration of olanzapine therapy. The average length of stay was longer in the HD-olanzapine group (31.3 days vs 14.5,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009). Constipation was more common in the HD-olanzapine group (8.6% vs 1.4%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0418).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although 30-day all-cause readmissions and emergency-treatment service visits were similar between groups, patients who received olanzapine doses of 40 mg\/day or greater for at least 5 days of treatment experienced significantly longer average length of stay and more constipation during an admission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.9740\/mhc.2026.08.196","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:39:12Z","timestamp":1786124352000},"page":"196-201","source":"Crossref","is-referenced-by-count":0,"title":["High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients"],"prefix":"10.9740","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3432-402X","authenticated-orcid":true,"given":"Teressa","family":"Benbarka","sequence":"first","affiliation":[{"name":"PGY-2 Psychiatric Pharmacy Resident, Riverside University Health System Medical Center, Riverside, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-414X","authenticated-orcid":true,"given":"Andrew","family":"Williams","sequence":"additional","affiliation":[{"name":"(Corresponding author) Supervising Clinical Pharmacist, Riverside University Health System Medical Center, Riverside, CA, Andrew.williams@ruhealth.org"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"1","key":"i2168-9709-16-4-196-b01","series-title":"J Psychopharmacol","first-page":"3","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","unstructured":"Barnes TR,\nDrake R,\nPaton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. DOI: 10.1177\/0269881119889296"},{"issue":"2","key":"i2168-9709-16-4-196-b02","series-title":"CNS Drugs","first-page":"149","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen","year":"2016","unstructured":"Nielsen J,\nYoung C,\nIfteni P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149-61. DOI: 10.1007\/s40263-016-0311-1"},{"issue":"5","key":"i2168-9709-16-4-196-b03","series-title":"World J Biol Psychiatry","first-page":"318","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","unstructured":"Hasan A,\nFalkai P,\nWobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-78. DOI: 10.3109\/15622975.2012.696143"},{"issue":"5","key":"i2168-9709-16-4-196-b04","series-title":"Aust N Z J Psychiatry","first-page":"410","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","unstructured":"Galletly C,\nCastle D,\nDark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-72. DOI: 10.1177\/0004867416641195"},{"issue":"9","key":"i2168-9709-16-4-196-b05","series-title":"Am J Psychiatry","first-page":"868","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","unstructured":"Keepers GA,\nFochtmann LJ,\nAnzia JM, et al. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-72. DOI: 10.1176\/appi.ajp.2020.177901"},{"issue":"6","key":"i2168-9709-16-4-196-b06","series-title":"Hum Psychopharmacol","first-page":"e2804","article-title":"Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms","volume":"36","author":"Takeuchi","year":"2021","unstructured":"Takeuchi H,\nTakekita Y,\nHori H, et al. Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. Hum Psychopharmacol. 2021;36(6):e2804. DOI: 10.1002\/hup.2804"},{"issue":"3","key":"i2168-9709-16-4-196-b07","series-title":"Neuropsychopharmacol Rep","first-page":"266","article-title":"Japanese Society of Neuropsychopharmacology: \u201cGuideline for Pharmacological Therapy of Schizophrenia","volume":"41","author":"Japanese Society of Neuropsychopharmacology","year":"2021","unstructured":"Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: \u201cGuideline for Pharmacological Therapy of Schizophrenia.\u201d Neuropsychopharmacol Rep. 2021;41(3):266-324. DOI: 10.1002\/npr2.12193"},{"issue":"3","key":"i2168-9709-16-4-196-b08","series-title":"Am J Psychiatry","first-page":"216","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","unstructured":"Howes OD,\nMcCutcheon R,\nAgid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-29. DOI: 10.1176\/appi.ajp.2016.16050503"},{"key":"i2168-9709-16-4-196-b09","article-title":"Bethesda: ZYPREXA- olanzapine tablet ZYPREXA ZYDIS- olanzapine tablet, orally disintegrating ZYPREXA INTRAMUSCULAR- olanzapine injection, powder, for solution","author":"DailyMed.nlm.nih.gov [Internet]","year":"2025","unstructured":"DailyMed.nlm.nih.gov [Internet]. Bethesda: ZYPREXA- olanzapine tablet ZYPREXA ZYDIS- olanzapine tablet, orally disintegrating ZYPREXA INTRAMUSCULAR- olanzapine injection, powder, for solution; [cited 17 Dec 2025]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341"},{"issue":"12","key":"i2168-9709-16-4-196-b10","series-title":"N Engl J Med","first-page":"1209","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","unstructured":"Lieberman JA,\nStroup TS,\nMcEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. DOI: 10.1056\/NEJMoa051688"},{"issue":"7","key":"i2168-9709-16-4-196-b11","series-title":"Expert Rev Neurother","first-page":"1045","article-title":"Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction","volume":"9","author":"Citrome","year":"2009","unstructured":"Citrome L,\nKantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9(7):1045-58. DOI: 10.1586\/ern.09.54"},{"issue":"1","key":"i2168-9709-16-4-196-b12","series-title":"Biol Psychiatry","first-page":"52","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","unstructured":"Tollefson GD,\nBirkett MA,\nKiesler GM,\nWood AJ, Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. DOI: 10.1016\/s0006-3223(00)01026-x"},{"issue":"2","key":"i2168-9709-16-4-196-b13","series-title":"J Clin Psychiatry","first-page":"274","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","unstructured":"Meltzer HY,\nBobo WV,\nRoy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274-85. DOI: 10.4088\/jcp.v69n0214"},{"issue":"1","key":"i2168-9709-16-4-196-b14","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"173","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","unstructured":"Bitter I,\nDossenbach MRK,\nBrook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):173-80. DOI: 10.1016\/j.pnpbp.2003.09.033"},{"issue":"2","key":"i2168-9709-16-4-196-b15","series-title":"Am J Psychiatry","first-page":"255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","unstructured":"Volavka J,\nCzobor P,\nSheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255-62. DOI: 10.1176\/appi.ajp.159.2.255"},{"issue":"7","key":"i2168-9709-16-4-196-b16","series-title":"Can J Psychiatry","first-page":"701","article-title":"Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study","volume":"44","author":"Dursun","year":"1999","unstructured":"Dursun SM,\nGardner DM,\nBird DC,\nFlinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry. 1999;44(7):701-4. DOI: 10.1177\/070674379904400709"},{"issue":"4","key":"i2168-9709-16-4-196-b17","series-title":"J Clin Psychopharmacol","first-page":"448","article-title":"Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial","volume":"21","author":"Lindenmayer","year":"2001","unstructured":"Lindenmayer JP,\nVolavka J,\nLieberman J, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol. 2001;21(4):448-53. DOI: 10.1097\/00004714-200108000-00014"},{"issue":"5","key":"i2168-9709-16-4-196-b18","series-title":"Psychiatry Clin Neurosci","first-page":"478","article-title":"Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial","volume":"57","author":"Chiu","year":"2003","unstructured":"Chiu NY,\nYang YK,\nChen PS,\nChang CC,\nLee IH,\nLee JR. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. Psychiatry Clin Neurosci. 2003;57(5):478-84. DOI: 10.1046\/j.1440-1819.2003.01151.x"},{"issue":"1","key":"i2168-9709-16-4-196-b19","series-title":"Asian J Psychiatry","first-page":"86","article-title":"Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia","volume":"6","author":"Kishi","year":"2013","unstructured":"Kishi T,\nSuzuki T,\nSekiguchi H, et al. Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. Asian J Psychiatry. 2013;6(1):86-7. DOI: 10.1016\/j.ajp.2012.08.006"},{"issue":"2","key":"i2168-9709-16-4-196-b20","series-title":"Clin Neuropharmacol","first-page":"58","article-title":"High-dose olanzapine for treatment-refractory schizophrenia","volume":"26","author":"Lerner","year":"2003","unstructured":"Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol. 2003;26(2):58-61. DOI: 10.1097\/00002826-200303000-00003"},{"issue":"4","key":"i2168-9709-16-4-196-b21","series-title":"Prim Care Companion J Clin Psychiatry","first-page":"244","article-title":"High-dose olanzapine orally disintegrating tablets for treatment-resistant psychosis","volume":"8","author":"Qadri","year":"2006","unstructured":"Qadri SF,\nPadala PR,\nStrunk JC,\nBoust SJ. High-dose olanzapine orally disintegrating tablets for treatment-resistant psychosis. Prim Care Companion J Clin Psychiatry. 2006;8(4):244-5. DOI: 10.4088\/pcc.v08n0410a"},{"issue":"7","key":"i2168-9709-16-4-196-b22","series-title":"Am J Psychiatry","first-page":"914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","unstructured":"Conley RR,\nTamminga CA,\nBartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155(7):914-20. DOI: 10.1176\/ajp.155.7.914"},{"issue":"6","key":"i2168-9709-16-4-196-b23","series-title":"J Clin Psychopharmacol","first-page":"668","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study","volume":"23","author":"Conley","year":"2003","unstructured":"Conley RR,\nKelly DL,\nRichardson CM,\nTamminga CA,\nCarpenter WT. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23(6):668-71. DOI: 10.1097\/01.jcp.0000096246.29231.73"},{"key":"i2168-9709-16-4-196-b24","series-title":"Ther Adv Psychopharmacol","article-title":"High-dose olanzapine in treatment-resistant schizophrenia: a systematic review","volume":"13","author":"Gannon","year":"2023","unstructured":"Gannon L,\nReynolds J,\nMahon M,\nGaughran F,\nLally J. High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. Ther Adv Psychopharmacol. 2023;13:20451253231168788. DOI: 10.1177\/20451253231168788"},{"issue":"2-3","key":"i2168-9709-16-4-196-b25","series-title":"Schizophr Res","first-page":"604","article-title":"A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"150","author":"Ermilov","year":"2013","unstructured":"Ermilov M,\nGelfin E,\nLevin R, et al. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr Res. 2013;150(2-3):604-5. DOI: 10.1016\/j.schres.2013.09.018"},{"issue":"1","key":"i2168-9709-16-4-196-b26","series-title":"Clin Toxicol (Phila PA)","first-page":"39","article-title":"Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care","volume":"52","author":"Petersen","year":"2014","unstructured":"Petersen AB,\nAndersen SE,\nChristensen M,\nLarsen HL. Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clin Toxicol (Phila PA). 2014;52(1):39-43. DOI: 10.3109\/15563650.2013.862258"},{"key":"i2168-9709-16-4-196-b27","series-title":"Gen Hosp Psychiatry","first-page":"53","article-title":"Pre- and post-discharge factors influencingearly readmission to acute psychiatric wards: implications for quality-of-care indicators in psychiatry","volume":"39","author":"Donisi","year":"2016","unstructured":"Donisi V,\nTedeschi F,\nSalazzari D,\nAmaddeo F. Pre- and post-discharge factors influencingearly readmission to acute psychiatric wards: implications for quality-of-care indicators in psychiatry. Gen Hosp Psychiatry. 2016;39:53-8. DOI: 10.1016\/j.genhosppsych.2015.10.009"},{"key":"i2168-9709-16-4-196-b28","series-title":"Psychiatry Res","first-page":"113309","article-title":"Factors associated with 30-days and 180-days psychiatric readmissions: a snapshot of a metropolitan area","volume":"292","author":"Del Favero","year":"2020","unstructured":"Del Favero E,\nMontemagni C,\nVillari V,\nRocca P. Factors associated with 30-days and 180-days psychiatric readmissions: a snapshot of a metropolitan area. Psychiatry Res. 2020;292:113309. DOI: 10.1016\/j.psychres.2020.113309"},{"issue":"4","key":"i2168-9709-16-4-196-b29","series-title":"J Healthc Qual","first-page":"228","article-title":"Predictors of 30-day postdischarge readmission to a multistate national sample of state psychiatric hospitals","volume":"41","author":"Ortiz","year":"2019","unstructured":"Ortiz G. Predictors of 30-day postdischarge readmission to a multistate national sample of state psychiatric hospitals. J Healthc Qual. 2019;41(4):228-36. DOI: 10.1097\/JHQ.0000000000000162"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/4\/article-p196.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/4\/article-p196.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/4\/article-p196.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:39:13Z","timestamp":1786124353000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/4\/article-p196.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2026.08.196","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}